

Comparative Study of Molecular Phylogeny, Adhesion Genes and Antibiogram of *Escherichia Coli* Clinical Isolates From High Vaginal Swabs and Urine in Women.

Mohanad Mohsin Ahmed^{^*}

[^] Department of Microbiology, College of medicine, University of Kerbala, Kerbala, Iraq

Abstract

Background: *Escherichia coli* is a frequent cause of urinary tract infections, however, its identity as pathogen in the cervico-vaginal area is required to be ascertained. In addition, source (s) for *E.coli* colonizing female vagina is needed to be confirmed, whether its fecal contamination or from urinary tract.

Aim of the Study: To perform a comparative analysis of the *E. coli* clinical isolates from vagina versus those from urine in terms of molecular phylogeny, molecular determinants of virulence and antimicrobial susceptibility.

Materials and methods: A total of 60 *E. coli* strains from high vaginal swabs (n=30) and urine (n=30) were analyzed. Identification of phylogenetic groups and detection of adhesive genes were conducted by 2 different multiplex PCR systems. Antibiograms for all isolates were performed by Kirby-Bauer method.

Results and Discussion: Majority of vaginal *E coli* (VEC) isolates were belong to B2 phylogenetic group (n=20, 66.7%), whereas, majority of uro-pathogenic *E. coli* (UPEC) isolates were distributed between two phylogenetic groups, namely B2 12 (40%) and D 11 (36.7%). Therefore, most of the strains from both vagina and urine are belonging to pathogenic phylogenetic groups; however, they differ in prevalence of the groups. The *pap* gene has a higher frequency among UPEC (n= 13, 43.3%) than in VEC isolates (n=7, 23.3%). Similarly, *sfa* gene has a higher frequency in VEC isolates (n= 20, 66.7%) than in UPEC isolates 11 (36.4%). Consequently, adhesion genes playing roles in vaginal colonization may differ from that in urinary tract .VEC strains were highly susceptible to ciprofloxacin (100%) followed by nitrofurantoin (73.3%) and nalidixic acid (70%). Whereas UPEC strains were highly susceptible to nitrofurantoin (100%) followed by nalidixic acid. Thus, it seems that cirpofloxacin is appropriate for empirical therapy in vaginal infections, whereas nitrofurantoin is more appropriate for empirical therapy in UTI.

Conclusion: Strains isolated from high vaginal swabs differ from strains isolated from urine in the prevalence of phylogenetic groups andmolecular determinants of virulence as well as in antibiograms.

Keywords: *E. coli*, *pap*, *sfa*, *afa*, high vaginal swab, Phylogeny

Introduction

Escherichia coli is a normal intestinal inhabitant of human. Nevertheless, several *E. coli* strains are frequent cause of an array of intestinal and extra-intestinal illnesses including

diarrhea, urinary tract infections, septicemia, and neonatal meningitis⁽¹⁾.

Certain virulence factors occur more frequently in urinary than in fecal isolates, suggesting that uropathogenic *E. coli* (UPEC) is different from normal intestinal inhabitants⁽²⁾. Although *E. coli* is frequently isolated from vaginal

*For Correspondence: Email to dr.mohma.med.school@gmail.com

epithelium⁽³⁾, it is not known whether vaginal *E. coli* (VEC) isolates is different from the intestinal inhabitants or the same. Furthermore, the precise identity of vaginal VEC as a pathogen is not clear. In addition, the source of VEC is not clearly determined, whether it is from faecal contamination or from urinary tract.

Several studies support the notion that vaginal colonization with *E. coli* is an important medical condition with serious implications. Vaginal colonization with *E. coli* have been reported in 9–28% of non-pregnant women⁽⁴⁾ and 24–31% of pregnant women⁽⁵⁾ and shown to be associated with several genitourinary, obstetric and neonatal complications, including pelvic inflammatory disease⁽⁶⁾. Vaginal colonization by *E. coli* was found to be a risk factor for very low birth weight delivery and other perinatal complications⁽³⁾.

Phylogenetic studies have divided *E. coli* into four major phylogenetic groups; A, B1, B2 and D⁽⁷⁾. Currently, phylogenetic studies are using simple and rapid technique based on triplex PCR that uses a combination of two genes (*chuA* and *yjaA*) and anonymous DAN fragment⁽⁷⁾. Indeed, *chuA*, is a gene required for heme transport in enterohemorrhagic O157:H7 *E. coli*⁽⁸⁾; *yjaA*, is a gene identified in the complete genome sequence of *E. coli* K-12 but its function is not known yet⁽⁹⁾; whereas, TSPE4.C2 is an anonymous DNA fragment with unknown function. Studies reported that virulent extra-intestinal strains frequently belong to group B2 and, to a less extent, to group D (7, 10-13), as well as that most commensal strains belong to group A (7, 13). Indeed, it was reported that virulence factor expression is more common among certain genetically related groups of *E. coli* which constitute virulent clones within the larger *E. coli* population. In general, the more virulence factors a strain expresses, the more severe an infection it is able to cause⁽²⁾.

The ability of bacteria to adhere to host epithelial cells is considered a necessity for the establishment of infectious diseases, mainly through expression of adhesins^(14, 15). The presence of adhesins is possibly the major determinant of the pathogenicity for uropathogenic *E. coli* (UPEC)⁽¹⁶⁾. These genes are reported to play roles in movement of *E. coli* from intestinal tract to urinary bladder and vagina and, consequently colonizing these sites⁽¹⁷⁾. Among the adhesins genes are type P fimbrial (*Pap*) gene, type S fimbrial adhesion gene (*sfa*), and the afimbrial adhesion gene (*afa*). Previous studies have shown that operons *pap*, *sfa*, and *afa* are prevalent in *E. coli* strains associated with urinary tract infections (pyelonephritis) in humans^(18, 19). In addition, the prevalence of adhesin genes was shown to differ between UPEC and fecal commensal strains of *E. coli*⁽²⁰⁾.

In studying the maternal carriage of extended-spectrum betalactamase-producing *E. coli* isolates, ESBL-producing *E. coli* were prevalent in pregnant women⁽²¹⁾. Studies from worldwide have reported isolation of drug resistant *E. coli* among vaginal isolates of pregnant women⁽²¹⁻²³⁾. Transmission of these resistant strains to the neonate can prove fatal in whom early detection is challenging and treatment options are limited. Outbreaks in neonatal wards and adverse outcome due to drug resistant *E. coli* infection have been reported^(24, 25). Thus identification and elimination of these resistant strains at the maternal level can have an impact on the reduction of fatal outcome in neonates especially in developing countries where the neonatal mortality rate is high⁽²⁶⁾. The overall aim of this study was to compare the *E. coli* isolates from genital tract and from urinary tract in terms of phylogeny, virulence and antibiotic susceptibility in order to shed light on the possible source of vaginal colonization/infection.

Materials and methods

E. coli clinical isolates

A total of 60 *E. coli* non-duplicated clinical isolates were included in this study (30 UPEC and 30 VEC). The isolates were collected over a period from December 2013 and June 2014 and all patients were attendants of the Gynaecology and Obstetrics teaching Hospital in Kerbala, Iraq. For UPEC isolates, clean midstream urine specimens from about 75 female patients with urinary tract infections were collected and processed by standard microbiological isolation and identification of *E. coli* (27). Regarding the VEC isolates, high vaginal swabs and/or endocervical swabs from 60 patients suffering from vaginal discharges and the swabs were processed for isolation and identification

of *E. coli* using standard microbiological techniques (27).

The determination of *E. coli* phylogenetic groups was performed by multiplex PCR as described by Clermont, *et al.* (7). Details of primer sequences and predicted sizes of the amplified products are shown in table 1. results interpretation are summarized in Table 1. Each reaction was carried out by using a 20 µl mixture containing premixed PCR components (Bioneer Inc., Korea), 20 pmol of each primer and 3 µl bacterial lysate. The PCR steps were as follows: denaturation for 5 min at 94°C, 30 cycles of 30 s at 94°C, 30s at 55°C, and 30s at 72°C; and a final extension step of 5 min at 72°C. PCR products were visualized by electrophoresis in 1.5% agarose and ethidium bromide staining.

Table 1. Primers for the PCR assays of *E. coli* phylogeny

Target gene	Primer sequence (5'-3')	Size of amplicon (bp)
ChuA	ChuA.1 GACGAACCAACGGTCAGGAT	279
	ChuA.2 TGCCGCCAGTACCAAAGACA	
YjaA	YjaA.1 TGAAGTGTGACAGGAGACGCTG	211
	YjaA.2 ATGGAGAATGCGTTCCTCAAC	
TspE4C2	TspE4C2.1 GAGTAATGTCTGGGGCATTCA	152
	TspE4C2.2 CGCGCCAACAAAGTATTACG	

The phylogenetic grouping of *E. coli* isolates was made on the basis of the presence of specific PCR-amplified fragments as follows(7):

- group A: (chu A -, yja A +/-, TspE4C2 -)
- group B1: (chu A -, yja A +/-, TspE4C2 +)
- group B2: (chu A+, yja A +, TspE4C2 +/-)
- group D: (chu A+, yja A -, TspE4C2 -/+)

Specific primers were used to amplify sequences of the *papC* (coding for P fimbriae), *sfa/foc* (coding for S fimbriae), and *afa* (afimbrial adhesin) operons as previously described (28). Details of primer

sequences and predicted sizes of the amplified products are summarized in Table 2. Each reaction was carried out by using a 20 µl mixture containing premixed (Bioneer Inc., Korea), 20 pmol of each primer and 3 µl bacterial lysate.

The PCR steps were as follows: denaturation for 5 min at 94°C, 30 cycles of 30 s at 94°C, 30 s at 65°C, and 30 s at 72°C ; and a final extension step of 5 min at 72°C. PCR products were visualized by electrophoresis in 1.5% agarose and ethidium bromide staining.

Table 2. Primers for the PCR assays of *E. coli* adhesive genes

Virulence factor	Target gene	Primer sequence (5'-3')	Size of amplicon (bp)
P fimbriae	<i>papC</i>	pap1 GACGGCTGTACTGCAGGGTGTGGCG	328
		pap2 ATATCCTTTCTGCAGGGATGCAATA	
S and FIC fimbriae	<i>sfa/foc</i> region	Sfa1 CTCCGGAGAAGTGGGTGCATCTTAC Sfa2 CGGAGGAGTAATTACAAACCTGGCA	410
Afa adhesins	<i>afa</i>	afa-f CGGCTTTTCTGCTGAACTGGCAGGC afa-r CCGTCAGCCCCACGGCAGACC	672

Results

Figure 1 represents a sample of phylogenetic determination of *E. coli* strains by multiplex PCR, whereas Figure 2, shows representative sample of results

for detection of adhesive genes by multiplex PCR. Phylogenetic groups were assigned according to the patterns generated by results of all 3 gene segments and as described previously⁽⁷⁾.




Figure 1. Agarose gel electrophoresis of *E. coli* phylogenetic group genes (*chu A*, *yja A* and DNA fragment *TSPE4.C2*) detected by multiplex PCR in 60 isolates of *E. coli*. **Lane (M)**, DNA molecular size marker (100-bp ladder). **Lanes (8)** group B₂ isolates showing amplification product of *yja A* (211bp) and negative result with all products of phylogenetic groups respectively. **Lanes (20), (19) and (14)** group B₂ isolates showing amplification products of *Chu A* and *Yja A* and *Chu A*, *Yja A* and *Tspe4.C2* (279 bp, 211 bp and 152bp) respectively.



Figure 2. Agarose gel electrophoresis of *E. coli* virulence genes (*papc*, *sfa* and *afa*) genes detected by multiplex PCR. **Lane (M)**, DNA molecular size marker (100-bp ladder). **Lanes (57), (24₁), and (72)** show positive results with *papc* and *sfa* virulence factors genes. **Lanes (32) and (97)** show negative results with all virulence genes. All **Lane** *E. coli* shows negative result with *afa* gene (672bp) only.

Prevalence of Phylogenetic groups and adhesins genes

Table 3 summarizes the the prevalence of the phylogenetic groups among the VEC and UPEC isolates. In this study, a highly significant difference ($P= 0.002$) was seen between VEC and UPEC isolates regarding the distribution of the phylogenetic groups. The phylogenetic

group B2 was the most frequent among the strains from both vaginal and urine isolates, however, the rate of B2 group was higher in VEC isolates (66.7%) in comparison to UPEC isolates (40.0%). Importantly, 11 strains from the UPEC were phylogenetic group D vs. 1 strain from VEC and, in contrast, 8 strains from the VEC were phylogenetic group A vs. 1 strain from UPEC.

Table 3. Prevalence of Phylogenetic groups

		VEC isolates	UPEC isolates
Phylogenetic group	A	8 (26.7%)	3 (10%)
	B1	1 (3.3%)	4 (13.3%)
	B2	20 (66.7%)	12 (40%)
	D	1 (3.3%)	11 (36.7%)
	Chi-sqaure	0.002*	

*Highly significant difference. VEC, vaginal *E. coli* isolates. UPEC, uropathogenic *E. coli* isolates

Table 4 summarizes the prevalence of the adhesion genes among the VEC and UPEC isolates. Although type P fimbrial gene (*Pap*) gene was present in higher rates among UPEC isolates (43.3%) compared to VEC (23%), this difference was not significant ($P= 0.085$). On the other hand, statistically significant difference ($P= 0.019$) was noted between VEC and UPEC isolates regarding the type S fimbrial adhesion gene (*sfa*). *sfa* was present in remarkably higher rates in VEC isolates (66.7%) in comparison to UPEC (36.4%) and that this adhesin gene was the

most prevalent among the VEC isolates. The afimbrial adhesion gene (*afa*) demonstrated lower frequencies among both types of isolates; nevertheless, its frequency among VEC isolates was higher (10%) than UPEC isolates (3.3%). In addition, no diifference could be seen between both type of isolates in respect to carrying single or multiple adhesins genes.

Collectively, these results shows that *sfa* adhesin gene is the most prevalent among the VEC isolates , whereas *pap* adhesin gene was the most prevalent among UPEC.

Table 4. Prevalence of adhesins genes

		VEC isolates	UPEC isolates	Chi-square
	<i>pap</i>	7 (23.3%)	13 (43.3%)	0.085
	<i>sfa</i>	20 (66.7%)	11 (36.4%)	0.019*
	<i>afa</i>	3 (10%)	1 (3.3%)	NC
Adhesins genes	none	8 (73.3 %)	9 (66.7%)	0.431
	Single gene	14	17	
	multiple genes	8 (26.7%)	4 (13.3%)	

*Statistically significant. VEC, vaginal *E. coli* isolates. UPEC, uropathogenic *E. coli* isolates. NC, not calculated because, numbers of some groups not fit with statistics.

Carrying virulence genes within phylogenetic groups

As shown in table 5, group B2 was the most associated with adhesins genes, however, the type of the adhesins gene was different according site from which the isolates were recovered. Among B2 of

VEC isolates, 85% were carrying *sfa* gene, whereas only 54.6% of UPEC isolates were carrying this gene. On the other hand, 63.6% of UPEC isolates of B2 group were carrying *pap* gene and this is higher than in VEC isolates that only (25%) carried this gene.

Antibiograms

Regarding the antibiotic susceptibility testing, both of VEC and UPEC isolates showed high resistance to ampicillin. UPEC demonstrated remarkably higher susceptibility rate ($P=0.000$) to ampicillin-clavulanic acid

(53.3%) in comparison to VEC isolates (0.0%). In contrast, UPEC isolates were less susceptible to ciprofloxacin (73.3%) than VEC isolates (100%) and this difference in ciprofloxacin susceptibility was highly significant ($P=0.006$).

Table 5. Distribution of adhesins genes according to the phylogenetic groups

Phylogenetic groups	VEC isolates			UPEC isolaes		
	pap	sfa	afa	pap	sfa	afa
A	1 out of 8 (12.5%)	2 out of 8 (25%)	2 out of 8 (25%)	1 out of 3 (33.3%)	1 out of 3 (33.3%)	1 out of 3 (33.3%)
B1	0 out of 1	1 out of 1	0 out of 1	1 out of 4 (25%)	1 out of 4 (25%)	0 out of 4 (0.0%)
B2	5 out of 20 (25%)	17 out of 20 (85%)	1 out of 20 (5%)	7 out of 11 (63.6%)	6 out of 11 (54.6%)	0 out of 11 (0.0%)
D	1 out of 1	0 out of 0	0 out of 0	4 out of 12 (33.3%)	3 out of 12 (25%)	0 out of 12
Total	7	20	3	13	11	1

Higher resistance rate to nalidixic acid was detected among UPEC isolates (56.7%), compared to only 7 (6.7%) resistant to this antimicrobial among VEC isolates. However, this difference was not statistically significant ($P=0.091$). In

contrast, all UPEC isolates were susceptible to nitrofurantoin (100%), whereas, only 22 (73.3%) of the cervico-vaginal isolates were susceptible to this antimicrobial and this difference in susceptibility to nitrofurantoin was statistically significant ($P=0.010$).

Table 6. Antibiograms of *E. coli* isolated from high vaginal swabs and urine

Antibiotic	VEC isolates			UPEC isolates			Chi-square
	S	R	I	S	R	I	
Ampicillin	0	29 (96.7%)	1 (3.3%)	2 (6.7%)	28 (93.3%)	0	0.355
Ampicillin-clavulanic acid	0	28 (93.3%)	2 (6.7%)	16 (53.3%)	8 (26.7%)	6 (20.0%)	0.000*
Ciprofloxacin	30 (100%)	0	0	22 (73.3%)	8 (26.7%)	0	0.006*
Nalidixic Acid	21 (70%)	7 (23.3%)	2 (6.7%)	12 (40%)	17 (56.7%)	1 (3.3%)	0.091
Nitrofurantoin	22 (73.3%)	6 (20%)	2 (6.7%)	30 (100%)	0	0	0.010**

VEC, vaginal *E. coli*. UPEC, uropathogenic *E. coli*. S, Susceptible. R, Resistant. I, Intermediate.

* Highly significant. ** Significant.

Discussion

In this study, majority of VEC isolates were belong to B2 phylogenetic group (n=20, 66.7%), whereas, majority of UPEC were distributed between two phylogenetic groups, namely B2 12 (40%) and D 11 (36.7%). Owing to the fact that both B2 and D groups are pathogenic^{(7, 10-}

¹³⁾, most of the isolates from both types of samples in this study could be considered as pathogenic, and especially that *E. coli* colonizing the vaginal epithelium is pathogenic albeit it differs from the UPEC strains. In addition, the difference in the distribution of the phylogenetic groups

between VEC and UPEC isolates was a highly significant ($P= 0.002$). These results may point into two important attributes, first is that, *E. coli* strains colonizing the vaginal epithelium are pathogenic and, second, the strains from vagina may be different from strains isolated from urine.

To further investigate the similarity/ dissimilarity between VEC and UPEC isolates, we studied the carrying of adhesion genes. Indeed, epidemiologic investigations have shown a good correlation between the occurrence of certain human diseases and the presence of specific virulence factors in *E. coli* ⁽²⁹⁾.

In this study, we selected three adhesion genes. These genes are reported to play roles in movement of *E. coli* from intestinal tract to urinary bladder and vagina and, consequently colonizing these sites ⁽¹⁷⁾. Operons encoding P, S, and *afa* adhesins contribute to the pathophysiology of urinary tract infections, whereas genes encoding for S fimbriae is correlated with the pathogenesis of neonatal meningitis ⁽³⁰⁾.

In the present study, the presence of *pap* and *sfa* genes varies between VEC and UPEC strains, where *pap* gene has a higher frequency among UPEC than in VEC isolates. Similarly, *sfa* gene has a higher frequency in VEC isolates than in UPEC isolates. These results suggest that type P fimbriae are able to promote adherence to epithelial cells of the urinary tract more than epithelial cells of the vagina and that, in contrast, the type S fimbriae are able to promote adherence to epithelial cells of the vagina more efficiently than the urinary tract. In urinary tract infections, P-fimbriae mediate the specific attachment of UPEC to kidney tissue and elicit a cytokine response in these cells ^(2, 31). Nevertheless, the role of P-fimbriae in genital tract infection remains unknown.

Collectively, the results of this study show that *sfa* adhesin gene is the

most prevalent among the VEC isolates, whereas *pap* adhesin gene was the most prevalent among UPEC. Furthermore, the high prevalence of *sfa* gene among VEC isolates in this study may explain the high prevalence of this gene in *E. coli* strains isolated from neonatal meningitis in other studies ⁽³⁰⁾. And this finding may give additional evidence on the role of vaginal colonization in development of neonatal meningitis. In addition, the present study confirms that VEC strains possess several virulence factors allowing vaginal and/or endocervical colonization and this gives further support to previous studies that showed that VEC strains possess several virulence factors ^(32, 33).

In the current study, only one strain of UPEC possess *afa* gene vs. 3 VEC strains. Previous studies showed that Afa/Dr fimbrial adhesins contributed to the ability of UPEC isolates to colonize and persist long term within the urinary tract and therefore more likely to cause the recurrence of UTI episodes ^(34, 35).

Studying the antibiograms of VEC and UPEC isolates has demonstrated two important findings. First finding is that *E. coli* isolates colonizing vaginal epithelium are drug resistant and may comprise a risk factor especially for the neonates during delivery. Second finding is that there are differences in resistance patterns between VEC and UPEC isolates. The latter findings may have several implications, such as that supporting the hypothesis that *E. coli* colonizing the vagina are different from UPEC, and treatment appropriate for UPEC is not necessarily effective against VEC isolates.

In this study, VEC strains were highly susceptible to ciprofloxacin (100%) followed by Nitrofurantoin (73.3%) and Nalidixic acid (70%). Whereas UPEC strains were highly susceptible to nitrofurantoin (100%) followed by Nalidixic acid. Thus, it seems that Ciprofloxacin is appropriate for empirical therapy in vaginal infections, whereas Nitrofurantoin is more appropriate for

empirical therapy in UTI. Ciprofloxacin is the most commonly recommended therapy for UTIs during the last 10 years⁽³⁶⁻³⁸⁾. However, this study may indicate a decline in the susceptibility rate to this antibiotic among UPEC strains.

In conclusion, most of the strains from high vaginal swab and urine were shown to belong to the pathogenic phylogenetic groups and carrying molecular determinants of virulence. However, strains isolated from high vaginal swabs differ from strains isolated from urine in type of the prevalence of the phylogenetic groups and virulence factors as well as in antibiogram.

References

- Orskov, F. and I. Orskov, *Escherichia coli* serotyping and disease in man and animals. *Can J Microbiol*, 1992. **38**:p. 699-704.
- Johnson, J.R., Virulence factors in *Escherichia coli* urinary tract infection. *Clin Microbiol Rev*, 1991. **4**:p. 80-128.
- Krohn, M.A., et al., Vaginal colonization by *Escherichia coli* as a risk factor for very low birth weight delivery and other perinatal complications. *J Infect Dis*, 1997. **175**:p. 606-10.
- Chow, A.W., et al., Vaginal colonization with *Escherichia coli* in healthy women. Determination of relative risks by quantitative culture and multivariate statistical analysis. *Am J Obstet Gynecol*, 1986. **154**:p. 120-6.
- Hillier, S.L., et al., The normal vaginal flora, H₂O₂-producing lactobacilli, and bacterial vaginosis in pregnant women. *Clin Infect Dis*, 1993. **16 Suppl 4**: p. S273-81.
- Heinonen, P.K. and A. Miettinen, Laparoscopic study on the microbiology and severity of acute pelvic inflammatory disease. *Eur J Obstet Gynecol Reprod Biol*, 1994. **57**: p. 85-9.
- Clermont, O., S. Bonacorsi, and E. Bingen, Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl Environ Microbiol*, 2000. **66**:p. 4555-8.
- Bonacorsi, S.P., et al., Identification of regions of the *Escherichia coli* chromosome specific for neonatal meningitis-associated strains. *Infect Immun*, 2000. **68**:p. 2096-101.
- Blattner, F.R., et al., The complete genome sequence of *Escherichia coli* K-12. *Science*, 1997. **277**:p. 1453-62.
- Bingen, E., et al., Phylogenetic analysis of *Escherichia coli* strains causing neonatal meningitis suggests horizontal gene transfer from a predominant pool of highly virulent B2 group strains. *J Infect Dis*, 1998. **177**:p. 642-50.
- Boyd, E.F. and D.L. Hartl, Chromosomal regions specific to pathogenic isolates of *Escherichia coli* have a phylogenetically clustered distribution. *J Bacteriol*, 1998. **180**:p. 1159-65.
- Johnson, J.R. and A.L. Stell, Extended virulence genotypes of *Escherichia coli* strains from patients with urosepsis in relation to phylogeny and host compromise. *J Infect Dis*, 2000. **181**: p. 261-72.
- Soto, S.M., et al., Comparative study of virulence traits of *Escherichia coli* clinical isolates causing early and late neonatal sepsis. *J Clin Microbiol*, 2008. **46**:p. 1123-5.
- Valat, C., et al., Assessment of adhesins as an indicator of pathovar-associated virulence factors in bovine *Escherichia coli*. *Appl Environ Microbiol*, 2014.
- Klemm, P., V. Hancock, and M.A. Schembri, Fimbrial adhesins from extraintestinal *Escherichia coli*. *Environ Microbiol Rep*, 2010. **2**:p. 628-40.
- Mulvey, M.A., Adhesion and entry of uropathogenic *Escherichia coli*. *Cell Microbiol*, 2002. **4**:p. 257-71.
- Xie, J., et al., Molecular epidemiologic identification of *Escherichia coli* genes that are potentially involved in movement of the organism from the intestinal tract to the vagina and bladder. *J Clin Microbiol*, 2006. **44**:p. 2434-41.
- Hull, R.A., et al., Construction and expression of recombinant plasmids encoding type 1 or D-mannose-resistant pili from a urinary tract infection *Escherichia coli* isolate. *Infect Immun*, 1981. **33**:p. 933-8.
- Lindberg, F.P., B. Lund, and S. Normark, Genes of pyelonephritogenic *E. coli* required for digalactoside-specific agglutination of human cells. *EMBO J*, 1984. **3**:p. 1167-73.
- Johnson, J.R., et al., Bacterial characteristics in relation to clinical source of *Escherichia coli* isolates from women with acute cystitis or pyelonephritis and uninfected women. *J Clin Microbiol*, 2005. **43**: p. 6064-72.
- Villar, H.E., et al., Maternal carriage of extended-spectrum beta-lactamase-producing *Escherichia coli* isolates in Argentina. *J Chemother*, 2013. **25**:p. 324-7.
- Pathak, A., et al., Frequency and factors associated with carriage of multi-drug resistant commensal *Escherichia coli* among women attending antenatal clinics in central India. *BMC Infect Dis*, 2013. **13**: p. 199.

23. Al-Mayahie, S.M., Phenotypic and genotypic comparison of ESBL production by vaginal *Escherichia coli* isolates from pregnant and non-pregnant women. *Ann Clin Microbiol Antimicrob*, 2013. **12**: p. 7.
24. Moissenet, D., et al., Meningitis caused by *Escherichia coli* producing TEM-52 extended-spectrum beta-lactamase within an extensive outbreak in a neonatal ward: epidemiological investigation and characterization of the strain. *J Clin Microbiol*, 2010. **48**:p. 2459-63.
25. Boyer-Mariotte, S., et al., CTX-M-15-producing *Escherichia coli* in fatal neonatal meningitis: failure of empirical chemotherapy. *J Antimicrob Chemother*, 2008. **62**:p. 1472-4.
26. Million Death Study, C., et al., Causes of neonatal and child mortality in India: a nationally representative mortality survey. *Lancet*, 2010. **376**: p. 1853-60.
27. Collee, J.G., A.G. Fraser, and B.P. Marmion, Mackie & MacCartney practical medical Microbiology. 14 ed. 1996, London: Churchill Livingstone.
28. Soto, S.M., et al., Acquisition of a pathogenicity island in an *Escherichia coli* clinical isolate causing febrile urinary tract infection. *Eur J Clin Microbiol Infect Dis*, 2011. **30**:p. 1543-50.
29. Dalet, F., T. Segovia, and G. Del Rio, Frequency and distribution of uropathogenic *Escherichia coli* adhesins: a clinical correlation over 2,000 cases. *Eur Urol*, 1991. **19**:p. 295-303.
30. Huang, S.H., et al., *Escherichia coli* invasion of brain microvascular endothelial cells in vitro and in vivo: molecular cloning and characterization of invasion gene *ibe10*. *Infect Immun*, 1995. **63**:p. 4470-5.
31. Johnson, J.R., Virulence factors in *Escherichia coli*. *J Clin Microbiol*, 2005. **43**:p. 6221; author reply 6221-2.
32. Guiral, E., et al., Prevalence of *Escherichia coli* among samples collected from the genital tract in pregnant and nonpregnant women: relationship with virulence. *FEMS Microbiol Lett*, 2011. **314**:p. 170-3.
33. Birosova, E., et al., Detection of virulence factors in alpha-haemolytic *Escherichia coli* strains isolated from various clinical materials. *Clin Microbiol Infect*, 2004. **10**:p. 569-73.
34. Korotkova, N., et al., *Escherichia coli* DraE adhesin-associated bacterial internalization by epithelial cells is promoted independently by decay-accelerating factor and carcinoembryonic antigen-related cell adhesion molecule binding and does not require the DraD invasin. *Infect Immun*, 2008. **76**:p. 3869-80.
35. Dhakal, B.K., R.R. Kulesus, and M.A. Mulvey, Mechanisms and consequences of bladder cell invasion by uropathogenic *Escherichia coli*. *Eur J Clin Invest*, 2008. **38 Suppl 2**: p. 2-11.
36. Grover, V., et al., Galactose-specific fimbrial adhesin of enteroaggregative *Escherichia coli*: a possible aggregative factor. *Curr Microbiol*, 2007. **54**:p. 175-9.
37. Grover, M.L., et al., Assessing adherence to evidence-based guidelines for the diagnosis and management of uncomplicated urinary tract infection. *Mayo Clin Proc*, 2007. **8**:p. 181-5.
38. Kallen, A.J., H.G. Welch, and B.E. Sirovich, Current antibiotic therapy for isolated urinary tract infections in women. *Arch Intern Med*, 2006. **166**:p. 635-9.